Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ketamine Infusion as Sedative Analgesic in Severe ARDS (KISS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04818827
Recruitment Status : Completed
First Posted : March 26, 2021
Last Update Posted : March 26, 2021
Sponsor:
Information provided by (Responsible Party):
Ramakanth Pata, Interfaith Medical Center

Tracking Information
First Submitted Date March 19, 2021
First Posted Date March 26, 2021
Last Update Posted Date March 26, 2021
Actual Study Start Date February 1, 2020
Actual Primary Completion Date November 30, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: March 23, 2021)
All-Cause mortality [ Time Frame: 10 months (throughout the study period) ]
The two groups were compared for all-cause mortality during the ICU stay
Original Primary Outcome Measures Same as current
Change History No Changes Posted
Current Secondary Outcome Measures
 (submitted: March 23, 2021)
  • Hospital length of stay [ Time Frame: 10 months (throughout the study period) ]
    The two groups were compared for hospital length of stay
  • Duration of ventilator days [ Time Frame: 10 months (throughout the study period) ]
    The patients in two groups were compared for the duration of ventilator days
  • Infectious complications [ Time Frame: 10 months (throughout the study period) ]
    The patients in both groups were cultured as clinically suspected for infection. This included blood culture, urine culture and BAL/TTA
  • Acute Kidney Injury [ Time Frame: 10 months (throughout the study period) ]
    Routine blood samples were obtained that included serum creatinine. Acute kidney injury is defined as per KDIGO
  • Hemodynamic instability [ Time Frame: 10 months (throughout the study period) ]
    The patients were classified as hemodynamic instability if received vasopressors or ionotropes
  • Delirium after extubation [ Time Frame: 10 months (throughout the study period) ]
    All patients in the study were routinely screened for delirium using the CAM-ICU score
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Ketamine Infusion as Sedative Analgesic in Severe ARDS
Official Title Ketamine Infusion as Sedative Analgesic in Severe ARDS on Mechanically Ventilated Patients
Brief Summary To evaluate whether ketamine is a safe sedative-analgesic agent to be used in an intensive care unit (ICU) setting as compared to traditionally used agents such as propofol, opioids, and midazolam
Detailed Description

According to the 2018 Clinical Practice Guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the intensive care unit (ICU), nonbenzodiazepine sedatives (such as propofol and dexmedetomidine) are preferable to benzodiazepine sedatives (such as midazolam and lorazepam) in critically ill, mechanically ventilated patients. Moreover, continuous use of benzodiazepine (more than 48 hours) has been associated with a risk of prolonged sedation and delirium. On the other hand, though propofol has a remarkable safety profile, it carries unfavorable side effects such as dose-dependent hypotension, hypertriglyceridemia, pancreatitis, and propofol syndrome (which is a rare but potentially fatal complication, associated with high-dose propofol infusions, and characterized by severe metabolic acidosis and circulatory collapse).

During the coronavirus disease 2019 (COVID-19) pandemic, an enormous number of patients required mechanical ventilation, which led to the shortage of traditional sedatives such as propofol, dexmedetomidine, midazolam, and lorazepam in the hospitals. In this challenging time, ketamine was used as an alternative sedative infusion. This study is to evaluate whether ketamine is safer compared to other sedatives in severe COVID related ARDS patients.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population This study includes patients who are on mechanical ventilators and classified as moderate to severe ARDS with a PF ratio < 150.
Condition
  • Intensive Care Unit Syndrome
  • Mechanical Ventilation Complication
  • Sedatives and Hypnotics Causing Adverse Effects in Therapeutic Use
  • Delirium
Intervention Not Provided
Study Groups/Cohorts
  • Ketamine group
    This cohort includes patients who received ketamine as a sedative analgesic agent during mechanical ventilation
  • Non Ketamine group
    This cohort includes patients who received sedatives other than ketamine during mechanical ventilation
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: March 23, 2021)
124
Original Actual Enrollment Same as current
Actual Study Completion Date February 14, 2021
Actual Primary Completion Date November 30, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 with an arterial partial pressure of oxygen divided by the inspired oxygen concentration (P/F) ratio < 150 with a minimum 5 cm of positive end-expiratory pressure on a mechanical ventilator

Exclusion Criteria:

  • post-cardiac arrest status,
  • premorbid diagnosis of dementia,
  • dependency on extra-corporeal therapies prior to or during ICU stay
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 90 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT04818827
Other Study ID Numbers KISS 1.0
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: Yes
Plan Description: Willing to share all aspects of de-identified data
Supporting Materials: Study Protocol
Supporting Materials: Statistical Analysis Plan (SAP)
Supporting Materials: Clinical Study Report (CSR)
Time Frame: Available from March 30/2021
Access Criteria: Can be accessed via publishing journal
Responsible Party Ramakanth Pata, Interfaith Medical Center
Study Sponsor Interfaith Medical Center
Collaborators Not Provided
Investigators
Principal Investigator: RAMAKANTH PATA, MD Interfaith Medical Center
PRS Account Interfaith Medical Center
Verification Date March 2021